ANI Pharmaceuticals, Inc. Stock

Equities

ANIP

US00182C1036

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-04-17 pm EDT 5-day change 1st Jan Change
65.48 USD -0.12% Intraday chart for ANI Pharmaceuticals, Inc. -2.21% +18.75%
Sales 2024 * 534M Sales 2025 * 575M Capitalization 1.37B
Net income 2024 * 22M Net income 2025 * 34M EV / Sales 2024 * 2.42 x
Net cash position 2024 * 80.28M Net cash position 2025 * 188M EV / Sales 2025 * 2.06 x
P/E ratio 2024 *
50.9 x
P/E ratio 2025 *
31.9 x
Employees 642
Yield 2024 *
-
Yield 2025 *
-
Free-Float 80.97%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.12%
1 week-2.21%
Current month-5.28%
1 month-0.79%
3 months+17.77%
6 months+12.20%
Current year+18.75%
More quotes
1 week
65.02
Extreme 65.02
68.17
1 month
65.02
Extreme 65.02
70.81
Current year
53.47
Extreme 53.4746
70.81
1 year
36.99
Extreme 36.99
70.81
3 years
22.31
Extreme 22.31
70.81
5 years
22.31
Extreme 22.31
86.96
10 years
22.31
Extreme 22.31
86.96
More quotes
Managers TitleAgeSince
Chief Executive Officer 46 20-09-07
Director of Finance/CFO 53 16-05-05
Chairman 63 18-05-16
Members of the board TitleAgeSince
Director/Board Member 60 18-04-30
Director/Board Member 66 20-08-05
Director/Board Member 68 18-09-30
More insiders
Date Price Change Volume
24-04-17 65.48 -0.12% 123,206
24-04-16 65.56 -1.12% 99,004
24-04-15 66.3 -0.87% 111,916
24-04-12 66.88 -1.81% 94,984
24-04-11 68.11 +1.72% 136,646

Delayed Quote Nasdaq, April 17, 2024 at 04:00 pm EDT

More quotes
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company, which serves patients in need by developing, manufacturing and marketing branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Its three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products. The Company has a commercial portfolio of 116 products with a variety of indications and a robust portfolio of pipeline products. It has acquired the NDAs for and market Atacand, Atacand HCT, Arimidex, Casodex, Lithobid, Vancocin, Inderal LA, Inderal XL, InnoPran XL, Oxistat, Veregen, and Pandel. The Company sources the raw materials for its products from both domestic and international suppliers.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
65.48 USD
Average target price
79.8 USD
Spread / Average Target
+21.87%
Consensus